In this review:
Post chemo/RT durvalumab in locally advanced NSCLC
Front line osimertinib in EGFRm advanced NSCLC
Fixed-duration vs continuous nivolumab in advanced NSCLC
Minimal vs CT-based follow-up for completely resected NSCLC
Tumour mutational burden in blood & atezolizumab efficacy
Nivolumab vs nivolumab plus ipilimumab in MPM
Pembrolizumab in relapsed MPM
Dabrafenib + trametinib in BRAF V600E mutant metastatic NSCLC
CNS efficacy of alectinib vs crizotinib in treatment-naïve ALK+ NSCLC
Please login below to download this issue (PDF)